Related Experiment Video

Updated: Oct 15, 2025

Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration
07:59

Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration

Published on: April 4, 2022

1.4K

Evinacumab to treat hypercholesterolemia

C Engler1, C Ebenbichler2

  • 1Department for Internal Medicine I, Medical University Innsbruck, Innsbruck, Austria.

Drugs of Today (Barcelona, Spain : 1998)
|October 29, 2021
PubMed

Insights

Evinacumab effectively lowers cholesterol in patients with genetic dyslipidemias who don't respond to other treatments. This ANGPTL3 inhibitor significantly reduces cardiovascular risk factors by improving lipid levels.

Area of Science:

  • Cardiology
  • Biochemistry
  • Pharmacology

Background:

  • Cardiovascular disease (CVD) is a leading global cause of death, primarily driven by atherosclerosis.
  • Elevated low-density lipoprotein cholesterol (LDL-C) is a major risk factor for atherosclerosis.
  • Existing therapies and lifestyle changes are insufficient for some patients, particularly those with genetic dyslipidemias like familial hypercholesterolemia, leading to persistent high cardiovascular risk.

Purpose of the Study:

  • To evaluate the efficacy of evinacumab, a novel human monoclonal antibody, in managing dyslipidemia.
  • To assess the impact of ANGPTL3 inhibition on lipid profiles in patients with genetically induced dyslipidemias.
  • To determine if evinacumab can help patients reach their lipid targets and reduce cardiovascular risk.

Main Methods:

  • Evinacumab, a monoclonal antibody targeting angiopoietin-like protein 3 (ANGPTL3), was administered to patients.
  • The study assessed the drug's mechanism, involving increased lipoprotein lipase (LPL) and endothelial lipase (EL) activity.
  • Changes in circulating lipid levels, including very-low-density lipoprotein cholesterol (VLDL-C), triglycerides, LDL-C, and high-density lipoprotein cholesterol (HDL-C), were measured.

Main Results:

  • Evinacumab significantly reduced circulating levels of VLDL-C, triglycerides, LDL-C, and HDL-C.
  • The drug demonstrated increased activity of LPL and EL, key enzymes in lipid metabolism.
  • A significant decrease in overall lipids and achievement of lipid targets were observed in treated patients.

Conclusions:

  • Evinacumab is effective in significantly decreasing circulating lipids.
  • The ANGPTL3 inhibitor facilitates the attainment of lipid targets in patients with challenging dyslipidemias.
  • Further research is warranted to confirm evinacumab's long-term impact on cardiovascular risk and mortality.

Keywords:
Anti-angiopoietin-like protein 3 (ANGPTL3) agentsEvinacumabHypercholesterolemiaLipid-lowering therapyMetabolic diseasesMonoclonal antibodiesTreatment of lipoprotein disorders

More Related Videos

In vivo Near Infrared Fluorescence NIRF Intravascular Molecular Imaging of Inflammatory Plaque, a Multimodal Approach to Imaging of Atherosclerosis09:43

In vivo Near Infrared Fluorescence NIRF Intravascular Molecular Imaging of Inflammatory Plaque, a Multimodal Approach to Imaging of Atherosclerosis

Published on: August 4, 2011

18.2K
High-throughput Nitrobenzoxadiazole-labeled Cholesterol Efflux Assay08:18

High-throughput Nitrobenzoxadiazole-labeled Cholesterol Efflux Assay

Published on: January 7, 2019

9.2K

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
63
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
959
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
246
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
278
Endocarditis III: Medical Management01:18

Endocarditis III: Medical Management

Infective endocarditis management involves a multifaceted approach encompassing infection prevention, lifestyle modifications, pharmacological therapy, and surgical management.Infection Prevention:Hand Hygiene: Thorough handwashing is crucial to prevent the spread of infection. Hand hygiene should be performed regularly, especially before and after using the restroom.Oral Hygiene: Good oral hygiene is essential. It includes brushing teeth immediately after waking up and before bed, flossing...
45
Atherosclerosis IV: Nursing Management01:23

Atherosclerosis IV: Nursing Management

Nursing management for a patient with arteriosclerosis involves a comprehensive approach focusing on lifestyle modification, disease monitoring, education, and symptomatic care. Here is an overview of effective nursing strategies:Assessment and Monitoring: Initial and ongoing assessments are crucial. Nurses must document the patient's medical history, including any hypertension, diabetes, hyperlipidemia, and other cardiovascular diseases. Assessments also cover family history and lifestyle...
98